drugset / Trial / NCT02940418

Use of Stem Cells in Diabetes Mellitus Type 1

NCT02940418

Phase 1 Unknown 20 enrolled Sophia Al-Adwan
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Allogenic adipose derived mesenchymal stem cells will be injected into patients newly diagnosed with type 1 Diabetes Mellitus

Timeline

Start
2017-02-19
Primary completion
2019-11
Completion
2020-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator bone marrow mononuclear cells Cell therapy 1e+06 cells/kg Intravenous
Comparator bone marrow mononuclear cells Cell therapy 1e+07 cells/kg Intravenous
Comparator Adipose-derived mesenchymal cells Cell therapy Intravenous